

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 10/10/2018  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Lymphocyte Subset Panel 5 - Total Lymphocyte Enumeration**

ARUP test code 0095892

% CD3	48 %	L	(Ref Interval: 55-97)
Absolute CD3	92 cells/uL	L	(Ref Interval: 770-4000)
% CD4	17 %	L	(Ref Interval: 26-61)
Absolute CD4	32 cells/uL	L	(Ref Interval: 400-2500)
% CD8	30 %		(Ref Interval: 13-47)
Absolute CD8	58 cells/uL	L	(Ref Interval: 200-1700)
CD4:CD8 Ratio	0.57 ratio	L	(Ref Interval: 0.90-2.60)
% Natural Killer Cells	6 %		(Ref Interval: 2-31)
Absolute Natural Killer Cells	12 cells/uL	L	(Ref Interval: 70-590)
% CD19	41 %	H	(Ref Interval: 4-33)
Absolute CD19	78 cells/uL	L	(Ref Interval: 100-800)
Lymphocyte Subset Panel 5 Information	See Note		

H=High, L=Low, \*=Abnormal, C=Critical

**INTERPRETIVE INFORMATION: Lymphocyte Subset 5, Total Enumeration**  
 The CD4 cells are Helper T-cells expressing both CD3 and CD4. The CD8 cells are Cytotoxic T-cells expressing both CD3 and CD8. The B-cells express CD19, but not CD3. The NK-cells express either CD16 or CD56 (or both) but not CD3. CD3, CD4, CD8, CD19 and NK-cell percentages are reported as a percent of total lymphocytes. CD4 T-cell levels are a criterion for categorizing HIV-related clinical conditions by the CDC's classification system for HIV infection. The measurement of CD4 T-cell levels has been used to establish decision points for initiating P. jirovecii prophylaxis, antiviral therapy and to monitor the efficacy of treatment. The Public Health Service (PHS) has recommended that CD4 T-cell levels be monitored every three to six months in all HIV-infected persons.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
% CD3	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD3	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% CD4	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD4	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% CD8	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD8	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
CD4:CD8 Ratio	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% Natural Killer Cells	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute Natural Killer Cells	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
% CD19	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Absolute CD19	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Lymphocyte Subset Panel 5 Information	24-065-103933	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: